Arch Virol

1. PERDANA WY, Tsuneki-Tokunaga A, Rahmi KA, Hinay AA Jr, et al
   In vitro efficacy of anti-influenza active compounds against clinical isolates with high growth capability.
   Arch Virol. 2026;171:200.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

2. SHAO S, Dong ZY, Kang ZY, Zhang H, et al
   Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines.
   Biochem Biophys Res Commun. 2026;825:153958.
   

   >> Share

   
   

   
   Epidemiol Infect

3. SANE J
   Rebuilding trust in public health: Beyond polarization.
   Epidemiol Infect. 2026;154:e71.
   

   >> Share

   
   
4. HASSELL K, Andrews N, Dabrera G, Kall M, et al
   Acute COVID-19 mortality in England in the omicron era: a national-level matched cohort study.
   Epidemiol Infect. 2026;154:e70.
   

   >> Share

   
   

   
   J Infect Dis

5. PRASERT K, Praphasiri P, Ditsungnoen D, Naosri S, et al
   Risk of hospitalization related to influenza A(H3N2) virus subclade K, Thailand, June-December 2025.
   J Infect Dis. 2026 May 31:jiag283. doi: 10.1093.
   

   >> Share

   
   

   
   J Neurosurg Pediatr

6. ANDERSON MG, Pindrik J, Michelow IC, Anuar A, et al
   Pediatric sinogenic and otogenic intracranial infections requiring neurosurgical intervention: a North American multicenter study in the era of COVID-19.
   J Neurosurg Pediatr. 2026;37:621-631.
   

   >> Share

   
   

   
   J Virol

7. 
   CEIRR Risk Assessment Pipeline executive reports on H5N1 highly pathogenic avian influenza 2.3.4.4b, swine H1 1B.2, and H9N2 low pathogenicity avian influenza B4.7.2.
   J Virol. 2026 Jun 3:e0054526. doi: 10.1128/jvi.00545.
   

   >> Share

   
   
8. STEARNS K, Marcink T, Pawlack E, Sobolik EB, et al
   Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread.
   J Virol. 2026 Jun 3:e0212625. doi: 10.1128/jvi.02126.
   

   >> Share

   
   
9. TURNER AH, Jaffrani SA, Kubinski HC, Ajayi DP, et al
   Rab11B is required for binding and entry of recent H3N2, but not H1N1, influenza A isolates.
   J Virol. 2026 Jun 2:e0211125. doi: 10.1128/jvi.02111.
   

   >> Share

   
   

   
   Pediatrics

10. ROSTAD CA, Healy CM, Nayak JL, Parameswaran L, et al
    Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.
    Pediatrics. 2026 May 4:e2025075223. doi: 10.1542/peds.2025-075223.
    

    >> Share

    
    

    
    PLoS One

11. EKWUNIFE O, Mangenah C, Ngwira L, Corbett E, et al
    Economic barriers to diagnostic equity: A multi-country analysis of patient costs for rapid SARS-CoV-2 testing in sub-Saharan Africa.
    PLoS One. 2026;21:e0350288.
    

    >> Share

    
    
12. HEMBERG M, Hansen AL, Storgaard J, Blay-Cadanet J, et al
    MAVS is important for antiviral defense against influenza A virus in a human respiratory epithelium model.
    PLoS One. 2026;21:e0350839.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

13. RIKANI A, Di Domenico L, Sabbatini CE, Navarro V, et al
    Resetting population mobility responses under repeated nonpharmaceutical interventions: Implications for hypothesized pandemic fatigue.
    Proc Natl Acad Sci U S A. 2026;123:e2533284123.
    

    >> Share

    
    
14. PAPADAKI M, Pavlos E, Dubourdeau M, Bailif V, et al
    Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.
    Proc Natl Acad Sci U S A. 2026;123:e2534726123.
    

    >> Share

    
    
15. GRUNDY JG, Pujols-Beltran M
    Bilingualism predicts executive function resilience after COVID-19 in aging.
    Proc Natl Acad Sci U S A. 2026;123:e2532470123.
    

    >> Share

    
    

    
    Vaccine

16. DE FIGUEIREDO A, Paterson P, Lin L, Mounier-Jack S, et al
    Changing socio-demographic determinants of seasonal influenza acceptance in England during the pandemic and a framework for predicting future acceptance.
    Vaccine. 2026;85:128629.
    

    >> Share

    
    
17. DAS S, Tenaglia BM, Riley D, Speed S, et al
    BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy.
    Vaccine. 2026;87:128774.
    

    >> Share

    
    

    
    Virus Res

18. SEDAGHAT M, Najafi F, Khosravi Shademani F, Rezaeian S, et al
    Seasonal influenza vaccine and frequency of adverse events in health workers receiving two doses of AstraZeneca vaccine: a retrospective cohort study.
    Virus Res. 2026;369:199757.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share